GO:0141193 nuclear receptor-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0141193 describes the series of molecular signals initiated by a signaling molecule binding to an intracellular nuclear receptor, leading to regulation of downstream cellular processes such as transcription.
• Nuclear receptors are ligand-activated transcription factors that directly link signaling molecules to changes in gene expression.
• The pathway is highly conserved and regulates development, metabolism, reproduction, and immunity.
• Dysregulation of nuclear receptor signaling is implicated in cancer, metabolic disorders, and inflammatory diseases.
• Key experimental approaches include CRISPR knockout, point mutation, knock-in, and overexpression models to dissect receptor function.
• Understanding this pathway enables targeted drug discovery and precision medicine strategies.
Description
The nuclear receptor-mediated signaling pathway (GO:0141193) is a fundamental biological process in which signaling molecules, such as steroid hormones, thyroid hormones, and lipid metabolites, bind to intracellular nuclear receptors to regulate gene expression. This pathway is essential for translating extracellular and intracellular cues into transcriptional programs that control development, homeostasis, and metabolism. Nuclear receptors are a superfamily of ligand-activated transcription factors that directly interact with DNA to modulate target gene expression. The pathway is initiated when a ligand binds to a nuclear receptor, triggering conformational changes that allow the receptor to translocate to the nucleus, bind to hormone response elements, and recruit coactivators or corepressors. This process is critical for normal physiology and its dysregulation is associated with numerous diseases, including cancer, diabetes, and inflammatory disorders. Researchers study this pathway to understand how cells respond to hormonal and metabolic signals and to develop therapeutic interventions.
nuclear receptor-mediated signaling pathway At A Glance
| GO ID | GO:0141193 |
|---|---|
| GO term | nuclear receptor-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | nuclear receptor signaling pathway |
| Major function | Signal transduction from ligand binding to nuclear receptors leading to transcriptional regulation |
| Definition | The series of molecular signals initiated by a signaling molecule binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription. |
| Related pathways | Steroid hormone signaling, thyroid hormone signaling, retinoid signaling |
| Cellular location | Cytoplasm and nucleus |
| Key molecules | Nuclear receptors (e.g., ESR1, AR, GR, PPARs), ligands, coactivators, corepressors |
What Is GO:0141193?
The nuclear receptor-mediated signaling pathway (GO:0141193) is defined as the series of molecular signals initiated by a signaling molecule binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription. This process involves ligand binding, receptor activation, nuclear translocation, DNA binding, and modulation of target gene transcription.
Why Is nuclear receptor-mediated signaling pathway Important in Cell Biology?
The nuclear receptor-mediated signaling pathway is crucial because it directly connects signaling molecules to gene expression programs that control development, metabolism, reproduction, and immune responses. Dysregulation of this pathway is linked to major human diseases, including hormone-dependent cancers, metabolic syndrome, and inflammatory conditions. Understanding this pathway provides insights into basic biology and offers targets for therapeutic intervention.
• Regulates gene expression in response to hormones and metabolites.
• Controls development, differentiation, and organogenesis.
• Maintains metabolic homeostasis and energy balance.
• Modulates immune and inflammatory responses.
• Implicated in hormone-dependent cancers such as breast and prostate cancer.
• Plays a role in reproductive biology and fertility.
• Target for drug discovery, with many approved drugs targeting nuclear receptors.
• Involved in circadian rhythm and stress responses.
• Dysregulation leads to metabolic disorders like diabetes and obesity.
• Provides a paradigm for understanding intracellular signal transduction.
What Happens During nuclear receptor-mediated signaling pathway?
Ligand Binding and Receptor Activation
In simple terms: A signaling molecule binds to a nuclear receptor, causing it to change shape and become active.
The pathway begins when a signaling molecule, such as a steroid hormone, binds to the ligand-binding domain of a nuclear receptor in the cytoplasm or nucleus. This binding induces a conformational change that releases corepressors and recruits coactivators, activating the receptor. For example, estrogen binding to the estrogen receptor (ESR1) triggers receptor dimerization and activation.
Nuclear Translocation and DNA Binding
In simple terms: The activated receptor moves into the nucleus and attaches to specific DNA sequences.
Upon activation, many nuclear receptors translocate from the cytoplasm to the nucleus through nuclear pore complexes. Inside the nucleus, the receptor binds to specific DNA sequences known as hormone response elements (HREs) in the regulatory regions of target genes. This DNA binding is mediated by the receptor's DNA-binding domain, which recognizes specific consensus sequences.
Transcriptional Regulation
In simple terms: The receptor recruits other proteins to turn target genes on or off.
Once bound to DNA, the nuclear receptor recruits coactivator or corepressor complexes that modify chromatin and interact with the basal transcriptional machinery. This leads to either activation or repression of target gene transcription. For instance, ligand-bound estrogen receptor recruits coactivators such as SRC-1 to enhance transcription of estrogen-responsive genes.
Non-Genomic Signaling
In simple terms: Some nuclear receptors also trigger rapid signaling outside the nucleus.
In addition to their genomic actions, some nuclear receptors can mediate rapid, non-genomic signaling at the membrane or in the cytoplasm. For example, estrogen receptor can activate kinase cascades such as MAPK and PI3K/AKT within minutes of ligand binding. This non-genomic signaling can modulate cellular responses independently of transcription.
Feedback and Crosstalk
In simple terms: The pathway is fine-tuned by feedback loops and interactions with other signals.
Nuclear receptor signaling is subject to feedback regulation, including ligand availability, receptor phosphorylation, and degradation. Crosstalk with other signaling pathways, such as growth factor signaling, can modulate nuclear receptor activity. For example, EGF receptor-mediated phosphorylation can influence nuclear translocation of proteins, and ubiquitin ligases like Pellino1 can regulate STAT3, a transcription factor that interacts with nuclear receptor signaling.
Key Genes Involved in GO:0141193 nuclear receptor-mediated signaling pathway
The following genes encode key components of the nuclear receptor-mediated signaling pathway, including receptors, cofactors, and signaling molecules.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ESR1 | Estrogen receptor alpha; ligand-activated transcription factor | Breast cancer, hormone therapy |
| AR | Androgen receptor; mediates androgen signaling | Prostate cancer, androgen insensitivity |
| NR3C1 | Glucocorticoid receptor; stress response and metabolism | Inflammation, metabolic syndrome |
| PPARG | Peroxisome proliferator-activated receptor gamma; lipid metabolism | Diabetes, obesity |
| THRA | Thyroid hormone receptor alpha; development and metabolism | Thyroid disorders |
| RARA | Retinoic acid receptor alpha; differentiation | Acute promyelocytic leukemia |
| VDR | Vitamin D receptor; calcium homeostasis | Bone disorders, cancer |
| NCOA1 | Nuclear receptor coactivator 1; enhances transcription | Cancer, endocrine resistance |
| NCOR1 | Nuclear receptor corepressor 1; represses transcription | Cancer, metabolic disease |
| STAT3 | Signal transducer and activator of transcription 3; crosstalk | Inflammation, cancer |
| FUS | RNA-binding protein; nuclear translocation | Fibrotic signaling, neurodegeneration |
| IFI16 | Interferon-inducible protein; viral RNA sensing | Innate immunity, viral infection |
| PELI1 | E3 ubiquitin ligase; regulates STAT3 | Macrophage inflammation, tumor development |
| EGFR | Epidermal growth factor receptor; phosphorylates FUS | Fibrosis, cancer |
| CNR1 | Cannabinoid receptor 1; endocannabinoid signaling | Neurological disorders |
| CNR2 | Cannabinoid receptor 2; immune modulation | Inflammation, immune disorders |
| KPNB1 | Karyopherin beta 1; nuclear import receptor | Nuclear transport, cancer |
How Is nuclear receptor-mediated signaling pathway Regulated?
The nuclear receptor-mediated signaling pathway is regulated at multiple levels, including ligand availability, receptor expression, post-translational modifications, and interaction with coregulators. Phosphorylation of nuclear receptors by kinases such as MAPK can modulate their activity and localization. Ubiquitination and proteasomal degradation control receptor turnover. Additionally, crosstalk with other signaling pathways, such as growth factor signaling, can influence nuclear receptor function. For example, EGF receptor-mediated phosphorylation of FUS promotes its nuclear translocation and fibrotic signaling, and the ubiquitin ligase Pellino1 targets STAT3 to regulate macrophage-mediated inflammation.
nuclear receptor-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ESR1 | Breast cancer | CRISPR knockout in MCF-7 cells |
| AR | Prostate cancer | Point mutation knock-in in LNCaP cells |
| PPARG | Type 2 diabetes | Knockout in adipocytes |
| NR3C1 | Inflammatory diseases | Overexpression in macrophages |
| RARA | Acute promyelocytic leukemia | Knock-in of fusion gene in HL-60 cells |
Cancer
Dysregulation of nuclear receptor signaling is a hallmark of many cancers. Estrogen receptor alpha (ESR1) drives breast cancer proliferation, and anti-estrogen therapies are standard treatments. Androgen receptor (AR) signaling is critical in prostate cancer, where mutations or splice variants can confer resistance to therapy. Retinoic acid receptor alpha (RARA) translocations cause acute promyelocytic leukemia, which can be treated with retinoic acid and arsenic trioxide. Targeting nuclear receptors with small molecules remains a major therapeutic strategy.
Metabolic Disorders
Nuclear receptors such as PPARG, NR3C1, and THRA play central roles in glucose and lipid metabolism. PPARG agonists (thiazolidinediones) are used to treat type 2 diabetes. Glucocorticoid receptor (NR3C1) modulates inflammation and glucose homeostasis, and its dysregulation is linked to metabolic syndrome. Thyroid hormone receptor (THRA) mutations cause resistance to thyroid hormone, affecting growth and metabolism.
Inflammatory and Immune Diseases
Nuclear receptors modulate immune responses and inflammation. Glucocorticoids via NR3C1 are potent anti-inflammatory agents. The ubiquitin ligase Pellino1 regulates STAT3, which is involved in macrophage-mediated inflammation and tumor development. Cannabinoid receptors (CNR1, CNR2) are part of the endocannabinoid system and modulate immune function. Targeting these pathways is explored for treating autoimmune and inflammatory diseases.
Neurological and Fibrotic Disorders
Nuclear receptor signaling is implicated in neurodegeneration and fibrosis. FUS phosphorylation by EGFR promotes its nuclear translocation and fibrotic signaling. Cannabinoid receptor signaling influences neurological processes and has been studied in neurodegeneration. Understanding these mechanisms may lead to new therapies for fibrotic diseases and neurological disorders.
From nuclear receptor-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does the receptor drive tumor growth? | CRISPR knockout in cancer cell lines |
| How does a point mutation affect ligand binding? | Point mutation knock-in in HEK293 cells |
| What is the effect of receptor overexpression? | Overexpression in primary cells |
| Where is the receptor localized? | Tagged knock-in with fluorescent protein |
| What genes are regulated by the receptor? | Knockout followed by RNA-seq |
| Can a drug modulate receptor activity? | Reporter assays in knockout background |
How to Study the nuclear receptor-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify target genes of nuclear receptors |
| ChIP-seq | Genome-wide DNA binding sites | Map hormone response elements |
| Co-IP/MS | Protein-protein interactions | Identify coactivators/corepressors |
| Live-cell imaging | Receptor localization and dynamics | Track nuclear translocation |
| Reporter assays | Transcriptional activity | Screen for ligands or modulators |
| CRISPR screening | Functional gene identification | Discover novel pathway components |
| Proteomics | Protein expression and modifications | Analyze post-translational changes |
Transcriptomic Analysis
RNA sequencing (RNA-seq) is widely used to identify genes regulated by nuclear receptor signaling. By comparing wild-type and receptor-knockout cells, researchers can define the transcriptome controlled by specific nuclear receptors. This approach has revealed target gene networks for estrogen receptor, androgen receptor, and others.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) maps the genome-wide binding sites of nuclear receptors. This technique identifies hormone response elements and helps understand how receptors directly regulate transcription. It is often combined with RNA-seq to correlate binding with gene expression changes.
Protein-Protein Interaction Studies
Co-immunoprecipitation and mass spectrometry can identify coactivators and corepressors that interact with nuclear receptors. These methods elucidate the composition of transcriptional complexes and how they are regulated. For example, interactions between estrogen receptor and SRC-1 have been characterized.
Live-Cell Imaging
Fluorescence microscopy and live-cell imaging track the nuclear translocation and dynamics of nuclear receptors. Tagged receptors with fluorescent proteins allow real-time visualization of ligand-induced movement. This approach provides spatial and temporal insights into signaling.
How CRISPR Can Be Used to Study GO:0141193 nuclear receptor-mediated signaling pathway
Knockout
CRISPR knockout is used to completely ablate nuclear receptor genes to study their loss-of-function phenotypes. For example, knocking out ESR1 in breast cancer cells reveals its role in proliferation and gene expression. Knockout models help determine whether a receptor is required for specific signaling outputs.
Point Mutation
Point mutations can be introduced to mimic disease-associated mutations or to dissect functional domains. For instance, mutating the ligand-binding domain of a nuclear receptor can test its ligand dependency. Point mutation knock-in models are valuable for studying receptor variants found in patients.
Knock-in
Knock-in strategies allow the insertion of tags, reporters, or humanized sequences. Tagged knock-in of nuclear receptors with fluorescent proteins enables live-cell imaging of receptor dynamics. Knock-in of disease-associated mutations can create accurate disease models.
Overexpression
Overexpression of nuclear receptors or their cofactors is used to study gain-of-function effects and to amplify signaling. For example, overexpressing a constitutively active receptor can drive target gene expression even in the absence of ligand. Overexpression models are useful for drug screening and pathway analysis.
How EDITGENE Supports nuclear receptor-mediated signaling pathway Research
Researchers studying nuclear receptor-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in signaling outputs, and what its precise function is. EDITGENE provides comprehensive CRISPR-based services to create knockout, point mutation, knock-in, and overexpression cell models, as well as library screening and bioinformatics support, to accelerate your research.
Contact EDITGENE today to design your custom CRISPR model for nuclear receptor-mediated signaling pathway research.
Frequently Asked Questions About nuclear receptor-mediated signaling pathway
What is the nuclear receptor-mediated signaling pathway?
It is the series of molecular signals initiated by a signaling molecule binding to an intracellular nuclear receptor, leading to regulation of downstream cellular processes such as transcription.
What genes are involved in nuclear receptor-mediated signaling?
Key genes include ESR1, AR, NR3C1, PPARG, THRA, RARA, VDR, and their coactivators and corepressors.
What is GO:0141193?
GO:0141193 is the Gene Ontology identifier for the nuclear receptor-mediated signaling pathway, a biological process.
How does nuclear receptor signaling work?
A ligand binds to a nuclear receptor, causing a conformational change that leads to nuclear translocation, DNA binding, and transcriptional regulation of target genes.
What diseases are associated with nuclear receptor signaling?
Dysregulation is linked to cancer, metabolic disorders, inflammatory diseases, and neurological disorders.
What are nuclear receptors?
Nuclear receptors are a family of ligand-activated transcription factors that directly bind DNA to regulate gene expression.
How can I study nuclear receptor signaling?
Common methods include RNA-seq, ChIP-seq, CRISPR knockout, and live-cell imaging.
What is the role of estrogen receptor in signaling?
Estrogen receptor alpha (ESR1) mediates estrogen signaling, regulating genes involved in growth and proliferation, and is a key target in breast cancer.
Can CRISPR be used to study nuclear receptor signaling?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect receptor function.
What are the therapeutic implications of nuclear receptor signaling?
Many drugs target nuclear receptors, including anti-estrogens, anti-androgens, and PPAR agonists, making this pathway a major drug discovery focus.
Conclusion
The nuclear receptor-mediated signaling pathway (GO:0141193) is a central mechanism by which cells translate hormonal and metabolic signals into changes in gene expression. Its broad involvement in development, metabolism, immunity, and disease makes it a critical area of research. Understanding this pathway at the molecular level offers opportunities for therapeutic intervention and precision medicine.
References
- 1. Kato S. 2000. [Nuclear receptor-mediated signaling pathway].. Nihon Yakurigaku Zasshi 116(3):133-40 PMID: 11031742
- 2. Chiusa M et al.. 2020. EGF receptor-mediated FUS phosphorylation promotes its nuclear translocation and fibrotic signaling.. J Cell Biol 219(9) PMID: 32678881
- 3. Howlett AC. 2005. Cannabinoid receptor signaling.. Handb Exp Pharmacol PMID: 16596771
- 4. Ben Patel R et al.. 2025. Leveraging nuclear receptor mediated transcriptional signaling for drug discovery: Historical insights and current advances.. Adv Protein Chem Struct Biol 143:191-269 PMID: 39843136
- 5. Jiang Z et al.. 2021. IFI16 directly senses viral RNA and enhances RIG-I transcription and activation to restrict influenza virus infection.. Nat Microbiol 6(7):932-945 PMID: 33986530
- 6. Hwang S et al.. 2025. The ubiquitin ligase Pellino1 targets STAT3 to regulate macrophage-mediated inflammation and tumor development.. Nat Commun 16(1):1256 PMID: 39893188
- 7. Moriarty K et al.. 2006. Minireview: estrogen receptor-mediated rapid signaling.. Endocrinology 147(12):5557-63 PMID: 16946015
- 8. Pemberton LF et al.. 2005. Mechanisms of receptor-mediated nuclear import and nuclear export.. Traffic 6(3):187-98 PMID: 15702987
